SEC reporting owner
Flagship Ventures Fund IV General Partner LLC SEC insider disclosures
| Reporting owner CIK | 0001508051 |
|---|
| Issuers | 11 |
|---|
| Qualifying disclosures | 92 |
|---|
| Public purchases | 43 |
|---|
| Last public filing | 2023-07-14 |
|---|
| Coverage | verified |
|---|
| Directory rank | 22,028 |
|---|
Issuer relationships
- Eleven Biotherapeutics, Inc. (EBIO)
- T2 Biosystems, Inc. (TTOO)
- Seres Therapeutics, Inc. (MCRB)
- Editas Medicine, Inc. (EDIT)
- Syros Pharmaceuticals, Inc. (SYRS)
- Evelo Biosciences, Inc. (EVLO)
- Rubius Therapeutics, Inc. (RUBY)
- Moderna, Inc. (MRNA)
- Kaleido Biosciences, Inc. (KLDO)
- TransMedics Group, Inc. (TMDX)
Recent SEC transactions
No recent published transactions in the current window.
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.